Recruiting
The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI
NCT07479433· HeartFlow, Inc.· Source
Contact: Mara Caroline, MD
Enrolling by invitation
SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study
NCT07116668· SafeHeal Inc· Source
Active, not recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Active, not recruiting
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT06732401· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635· Phase 3· National Cancer Institute (NCI)· Source
Contact: Deric C. Savior (principal investigator)
Recruiting
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368· Medtronic Cardiovascular· Source
Contact: Eunita Chandardat
Recruiting
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844· Phase 3· National Cancer Institute (NCI)· Source
Contact: Deric C. Savior (principal investigator)
Not yet recruiting
Quelling of Excitotoxicity in Acute Stroke With Ketamine
NCT03223220· Phase 2/3· Lower Merion Neurology Research Foundation· Source
Contact: Sudhir Aggarwal, MD, PhD
Active, not recruiting
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Arezoo Ghaneie (principal investigator)
Active, not recruiting
Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
NCT05295628· Emblok, Inc.· Source
Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· Phase 3· SWOG Cancer Research Network· Source
Contact: Arezoo Ghaneie (principal investigator)
Recruiting
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· Phase 3· NRG Oncology· Source
Contact: Deric C. Savior (principal investigator)
Active, not recruiting
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05554328· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120· Weill Medical College of Cornell University· Source
Contact: Gianluca Torregrossa, MD
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377· Phase 2· National Cancer Institute (NCI)· Source
Contact: Paul B. Gilman (principal investigator)
Active, not recruiting
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317· Edwards Lifesciences· Source
Active, not recruiting
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Comparison of Left Bundle Branch Area Versus Right Ventricular Septal Pacing in Patients With High-degree Conduction Disease After Transcatheter Aortic Valve Replacement (Left Bundle BRAVE)
NCT05541679· Main Line Health· Source
Enrolling by invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536· Phase 3· Tolmar Inc.· Source
Recruiting
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT05640999· Phase 2· Canadian Cancer Trials Group· Source
Contact: Paul Gilman
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Gilead Sciences· Source
Active, not recruiting
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489· Phase 2· Shanghai Henlius Biotech· Source
Active, not recruiting
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection
NCT05174767· Artivion Inc.· Source
Active, not recruiting
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT05053152· Phase 2· NRG Oncology· Source
Active, not recruiting
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162· Phase 2/3· NRG Oncology· Source
Active, not recruiting
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283· Exact Sciences Corporation· Source
Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872· Edwards Lifesciences· Source
Contact: Edwards THV Clinical Affairs
Active, not recruiting
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395· Phase 3· Tolmar Inc.· Source
Recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334· Phase 2· National Cancer Institute (NCI)· Source
Contact: Paul B. Gilman (principal investigator)
Enrolling by invitation
Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting
NCT04451044· Philips Clinical & Medical Affairs Global· Source
Active, not recruiting
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250· Medtronic Cardiovascular· Source
Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
NCT04181060· Phase 3· National Cancer Institute (NCI)· Source
Contact: Paul B. Gilman (principal investigator)
Active, not recruiting
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
NCT04533451· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
NCT04316117· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Source
Contact: Paul B. Gilman (principal investigator)
Active, not recruiting
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
NCT04233866· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
NCT04310007· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· Phase 3· Actelion· Source
Recruiting
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
NCT04239573· ECOG-ACRIN Cancer Research Group· Source
Contact: Paul B. Gilman (principal investigator)
Recruiting
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848· Phase 3· National Cancer Institute (NCI)· Source
Contact: Deric C. Savior (principal investigator)
Active, not recruiting
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04248452· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT04092283· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
NCT04214067· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364· Phase 3· NRG Oncology· Source
Showing 50 of 104.